Phase 4
N=31
Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients
Pediatric HD · Bleeding
Bottom Line
View on ClinicalTrials.gov: NCT04376762 ↗Enrolled (actual)
31
Serious AEs
3.9%
Results posted
Mar 2026
Primary outcome: Primary: A Composite of the Number of Any Allogeneic Blood Products (RBCs, Plasma, Platelets, Cryoprecipitate) Transfused From Administration of the Study Medication Until 48 Hours After Surgery — 3.4; 4.5 allogeneic blood products
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Fibrinogen (Drug); Cryoprecipitate (Drug)
- Age
- Pediatric
- Sex
- All
- Sponsor
- University of Virginia
- Primary completion
- Mar 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY A Composite of the Number of Any Allogeneic Blood Products (RBCs, Plasma, Platelets, Cryoprecipitate) Transfused From Administration of the Study Medication Until 48 Hours After Surgery |
3.4; 4.5 | — |
| SECONDARY Comparison of Post CPB Bleeding (in ml) Between the Study Groups |
48.7; 46.2 | — |
| SECONDARY Comparison of the Number RBC Units Transfused Immediately After Administration of the Study Medication and Until Postoperative Day 7 |
0; 0 | — |
| SECONDARY Comparison of the Number Platelets Units Transfused Immediately After Administration of the Study Medication and Until Postoperative Day 7 |
1; 1 | — |
| SECONDARY Comparison of the Number Plasma Units Transfused Immediately After Administration of the Study Medication and Until Postoperative Day 7 |
0; 0 | — |
| SECONDARY Comparison of Additional Number Cryoprecipitate Units Transfused Immediately After Administration of the Study Medication and Until Postoperative Day 7 |
0; 0 | — |
| SECONDARY Number of Participants With Postoperative Surgical Chest Re-exploration for Excessive Bleeding/Cardiac Tamponade |
1; 0 | — |
| SECONDARY Incidence of the Use of Factor VIIa for Bleeding |
0; 3 | — |
| SECONDARY In-hospital Mortality |
0; 0 | — |
| SECONDARY Post Operative Acute Kidney Injury (AKI) |
1; 0 | — |
| SECONDARY Postoperative Infection |
0; 0 | — |
| SECONDARY Percent of Patients With Postoperative Neurological Injury |
0; 2 | — |
| SECONDARY Intubation Time |
NA; NA | — |
| SECONDARY Postoperative Thromboembolic Event |
0; 2 | — |
| SECONDARY ICU Length of Stay |
15.2; 10.5 | — |
| SECONDARY Hospital Length of Stay |
23.8; 15.5 | — |
Summary
The aim of the current pilot study proposal is to compare the use of the purified human fibrinogen concentrate (Fibryga®, Octapharma USA) to cryoprecipitate for the treatment of cardiopulmonary bypass (CPB)-associated bleeding in pediatric cardiac patients in whom fibrinogen supplementation is indicated.
The investigators' hypothesis is that fibrinogen concentrate will be as effective as cryoprecipitate in achieving adequate hemostasis after separation from CPB in pediatric cardiac surgery patients.
Study Design: this will be a single-center, prospective, randomized, active-control study in pediatric (24 months of age or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM). Informed consent will be obtained from a parent or a legal guardian prior to surgery and anesthesia. Once the need for fibrinogen supplementation is confirmed, study participants will be randomized into one of two treatment groups (n=15 in each group):
1. Cryoprecipitate group (dose: 10 ml/kg; active control group) or
2. Fibrinogen Concentrate group (dose: 70 mg/kg; intervention group). There will be no placebo group since withholding treatment is neither consistent with standard of care nor acceptable ethically. No other aspects of care will be modified. In the event that an additional dose of fibrinogen supplementation is required (bleeding with documented hypofibrinogenemia) cryoprecipitate will be administered to all study subjects (including those who received FC).
The results of this study will be used for publication as well as the first stage towards a significantly larger randomized multi-center trial (see below).
Based on the results of this pilot study the investigators plan to conduct a large multi-center, randomized active-control non-inferiority trial in the future, comparing the use of FC to cryoprecipitate in a much larger cohort of pediatric patients undergoing cardiac surgery with CPB. Ultimately, the results of this trial are likely to improve the care of pediatric cardiac surgical patients experiencing post-CPB bleeding, an under-studied yet high-risk patient population.
Eligibility Criteria
Inclusion Criteria
- pediatric (age 24 months or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM).
Exclusion Criteria
- gestational age < 33 weeks at birth
- gestational age < 35 weeks on the day of surgery
- emergency surgery
- patient or parent history of coagulopathy/clotting abnormalities
- patient history of thrombophilia
- refusal to participate in the study,
- known severe allergic reaction/anaphylaxis to fibrinogen concentrate,
- administration of fibrinogen concentrate or cryoprecipitate in the 24 hours prior to surgery
- baseline fibrinogen level higher than 300 mg/dL (to avoid the risk of increasing the fibrinogen level above the normal upper level of 400 mg/dL)
Data sourced from ClinicalTrials.gov (NCT04376762). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.